LXRX
Price
$0.82
Change
-$0.00 (-0.00%)
Updated
Jan 31, 11:23 AM (EDT)
Capitalization
298.34M
40 days until earnings call
NTLA
Price
$10.63
Change
+$0.12 (+1.14%)
Updated
Jan 31, 11:33 AM (EDT)
Capitalization
1.03B
20 days until earnings call
Ad is loading...

LXRX vs NTLA

Header iconLXRX vs NTLA Comparison
Open Charts LXRX vs NTLABanner chart's image
Lexicon Pharmaceuticals
Price$0.82
Change-$0.00 (-0.00%)
Volume$2.36K
Capitalization298.34M
Intellia Therapeutics
Price$10.63
Change+$0.12 (+1.14%)
Volume$1K
Capitalization1.03B
LXRX vs NTLA Comparison Chart
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. NTLA commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a StrongBuy and NTLA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (LXRX: $0.82 vs. NTLA: $10.51)
Brand notoriety: LXRX and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 82% vs. NTLA: 77%
Market capitalization -- LXRX: $298.34M vs. NTLA: $1.03B
LXRX [@Biotechnology] is valued at $298.34M. NTLA’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 2 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • LXRX’s TA Score: 2 bullish, 2 bearish.
  • NTLA’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than LXRX.

Price Growth

LXRX (@Biotechnology) experienced а -7.43% price change this week, while NTLA (@Biotechnology) price change was -6.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.08%. For the same industry, the average monthly price growth was +1.56%, and the average quarterly price growth was +5.26%.

Reported Earning Dates

LXRX is expected to report earnings on May 01, 2025.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.03B) has a higher market cap than LXRX($298M). LXRX YTD gains are higher at: 10.955 vs. NTLA (-9.863). LXRX has higher annual earnings (EBITDA): -198.7M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. LXRX (258M). LXRX (101M) and NTLA (102M) have identical debt. NTLA has higher revenues than LXRX: NTLA (43.1M) vs LXRX (5.23M).
LXRXNTLALXRX / NTLA
Capitalization298M1.03B29%
EBITDA-198.7M-527.52M38%
Gain YTD10.955-9.863-111%
P/E RatioN/AN/A-
Revenue5.23M43.1M12%
Total Cash258M658M39%
Total Debt101M102M99%
FUNDAMENTALS RATINGS
LXRX vs NTLA: Fundamental Ratings
LXRX
NTLA
OUTLOOK RATING
1..100
73
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6591
P/E GROWTH RATING
1..100
24100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (28) in the Biotechnology industry is in the same range as LXRX (60). This means that NTLA’s stock grew similarly to LXRX’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as LXRX (100). This means that NTLA’s stock grew similarly to LXRX’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as LXRX (99). This means that NTLA’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (65) in the Biotechnology industry is in the same range as NTLA (91). This means that LXRX’s stock grew similarly to NTLA’s over the last 12 months.

LXRX's P/E Growth Rating (24) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that LXRX’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXNTLA
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 24 days ago
90%
Bullish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 24 days ago
80%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 24 days ago
80%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 24 days ago
86%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 25 days ago
81%
Bullish Trend 30 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 24 days ago
90%
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGMAX26.210.30
+1.16%
Janus Henderson Triton A
QIACX48.24N/A
N/A
Federated Hermes MDT All Cap Core IS
TCGLX52.25N/A
N/A
Touchstone Large Company Growth C
PAILX7.95N/A
N/A
PGIM Jennison Intl Sm-Md Cap Opps C
PIGDX14.78N/A
N/A
Federated Hermes International Growth IS

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with EPIX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-0.71%
EPIX - LXRX
45%
Loosely correlated
+1.17%
FRTX - LXRX
41%
Loosely correlated
+0.32%
VCYT - LXRX
37%
Loosely correlated
+3.83%
NTLA - LXRX
36%
Loosely correlated
+3.85%
ABCL - LXRX
36%
Loosely correlated
+0.94%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+3.85%
VCYT - NTLA
69%
Closely correlated
+3.83%
EDIT - NTLA
68%
Closely correlated
+2.24%
BEAM - NTLA
62%
Loosely correlated
+5.29%
CRSP - NTLA
62%
Loosely correlated
+2.01%
PRME - NTLA
58%
Loosely correlated
+2.91%
More